MAPT and Alzheimer disease: Traditionally, AD diagnosis has relied on clinical assessment, supplemented by confirmatory tests such as cerebrospinal fluid (CSF) analysis and positron emission tomography (PET) imaging to detect amyloid and tau pathology [6].